Therefore, third-generation NKG2D CAR T cells were generated in the current study, and the addition of IL-15 and CCL19 resulted in fourth-generation CAR T cells with the goal of improving penetration, proliferation, survival, and tumor-killing abilities of CAR T cells in immunosuppressive tumor microenvironments. This evidence concerns the gene KLRK1 and neoplasm.